TriSalus Life Sciences Conference Call Summary Company Overview - Company: TriSalus Life Sciences (NasdaqGM: TLSI) - Focus: Improving drug delivery to pancreatic, liver, and solid tumors, with a specific emphasis on a drug called nelitolimod, an immunotherapeutic aimed at reversing immunosuppression in tumors [2][3] Industry Insights - Uterine Fibroids: The call highlighted uterine fibroid embolization as a preferable alternative to surgery for patients suffering from uterine fibroids [2][10] - Interventional Radiology (IR): The field has evolved significantly, with IR now recognized as a primary specialty in medicine, performing minimally invasive procedures using image guidance [12] Key Technology and Innovations - Pressure-Enabled Drug Delivery: TriSalus's technology modulates pressure and flow to enhance therapeutic delivery to tumors while minimizing exposure to normal tissues [3][5] - TriNav Infusion System: A proprietary system designed to improve the delivery of therapeutic agents, particularly in uterine artery embolization [8][10] - Smart Valve Technology: This technology allows for better perfusion of drugs into tumors by opening collapsed vessels and enhancing blood flow [5][6] Clinical Evidence and Outcomes - Uterine Artery Embolization (UAE): - UAE is effective for treating uterine fibroids and adenomyosis, providing significant symptomatic relief and a minimally invasive option compared to traditional surgical methods [16][19] - Clinical data showed that UAE is as effective as surgical alternatives, with a slightly higher re-intervention rate [19] - A study indicated a 100% technical and clinical success rate in patients using the TriNav catheter, with significant reductions in heavy menstrual bleeding and pain scores [26][27] Market Dynamics - Awareness and Education: There is a lack of awareness among patients and healthcare providers regarding UAE, with many women unaware of this treatment option [17][50] - Referral Pathways: Improved collaboration between interventional radiologists and gynecologists is essential to enhance patient access to UAE [50][53] - Cost-Effectiveness: The TriNav technology has been shown to be cost-saving due to reduced complications and improved therapeutic delivery, which is appealing to payers [65] Future Directions - Patient Education Initiatives: TriSalus plans to enhance patient education through social media and direct outreach to improve awareness of UAE [55][56] - Research and Data Publication: Ongoing efforts to publish clinical data supporting the efficacy of TriSalus's technologies will help influence treatment decisions among patients and providers [58] Conclusion TriSalus Life Sciences is positioned to make significant advancements in the treatment of uterine fibroids and solid tumors through innovative drug delivery technologies and a focus on patient education and awareness. The company aims to bridge the gap between interventional radiology and gynecology to improve patient outcomes and expand the adoption of minimally invasive procedures.
Trisalus Life Sciences (NasdaqGM:TLSI) Update / Briefing Transcript